Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ONCS $OHRP $OPGN On Watch
$JAGX On watch
I sold my all ATOS shares today.
$ADXS closing GAP... Next stop to $0.60...
$OPGN low float with low risk...
$ATOS free run to $0.45 (MA 200)
$ATOS ongoing three Ph II to breast cancer studies with $2 billion potential market...
$OPGN Next big runner to $15 per share...
$ATOS Massive short squeeze to $1 coming... Now or never...
$ATOS Massive short squeeze coming to $1 per share...
$OPGN Price Target in $10 share minimum
$ATOS alert! MACD in Bullish Mode and next testing MA200 in $0.45
$OPGN alert!
OPGN Lotto play with low float. Posible Massive Short Squeeze...
ATOS Close Gap and Bullish Crossing in MA200
APRI Oversold! Time to buy...
TENX Remember me CPRX years ago. With cash and Ph III pending for NDA.
TENX Remember me CPRX years ago. With cash and Ph III pending for NDA.
$OMER and $TENX
Omeros Corporation (OMER) and Tenax Therapeutics (TENX) : 2 Undervalued Biotechs
http://www.bolsatrading.eu/2017/11/omeros-corporation-omer-and-tenax.html
$ATOS have 2 Phase II for Breast Cancer: Fulvestrant Microcatheter with ductal carcinoma in-situ (DCIS) or invasive breast cancer slated for mastectomy or lumpectom and topical Endoxifen for the treatment of women with mammographic breast density, or MBD.
Minimum Valuation:$200MM Market Cap
2 Phase II for Breast Cancer: Fulvestrant Microcatheter with ductal carcinoma in-situ (DCIS) or invasive breast cancer slated for mastectomy or lumpectom and topical Endoxifen for the treatment of women with mammographic breast density, or MBD.
Minimum Valuation:$200MM Market Cap
$ATOS (Atossa Genetics) have a Market Cap only $10MM.
Learn CLDX example in this article. Phase II for breast cancer have Market Target: $5 Billion sales, and valuation with Market Cap of CLDX is $448MM. The valuation said that strong undervalued.
$$$$$$$$$$$$$$$$$$$$$$$$$$$
https://www.fool.com/investing/2016/12/19/how-to-value-clinical-stage-biotech-stocks.aspx
$ATOS (Atossa Genetics) have a Market Cap only $10MM.
Learn CLDX example in this article. Phase II for breast cancer have Market Target: $5 Billion sales, and valuation with Market Cap of CLDX is $448MM. The valuation said that strong undervalued.
$$$$$$$$$$$$$$$$$$$$$$$$$$$
https://www.fool.com/investing/2016/12/19/how-to-value-clinical-stage-biotech-stocks.aspx
Learn CLDX example in this article. Phase II for breast cancer have Market Target: $5 Billion sales, ante valuation with Market Cap of CLDX is $448MM. The valutation said that strong undervalued.
ATOS (Atossa Genetics) have a Market Cap only $10MM.
$$$$$$$$$$$$$$$$$$$$$$$$$$$
https://www.fool.com/investing/2016/12/19/how-to-value-clinical-stage-biotech-stocks.aspx
OPGN The big secret about this company...
https://www.genengnews.com/gen-news-highlights/opgen-merck-co-launch-antibiotic-resistance-collaboration/81253431
OPGN +15% With Strong Volume!
TENX +4.95%
AVGR the next MNKD!!!!!!
AVGR +7,81% with volume!!!!!